Regeneron Dividend Update: Insights Ahead of Ex-Dividend Date May 20, 2025
Generated by AI AgentAinvest Dividend Digest
Friday, May 16, 2025 7:15 pm ET1min read
REGN--
Regeneron Pharmaceuticals (REGN) has announced its latest dividend details, with an ex-dividend date set for May 20, 2025. The dividend was announced on Apr 29, 2025, and will be paid on Jun 6, 2025, at a rate of $0.880 per share. This amount is consistent with the average of the last 10 dividends per share, which also stands at $0.880, indicating stability in dividend disbursement. The previous dividend was paid on Mar 20, 2025, at the same rate, exemplifying the company's steady financial performance. The dividends are distributed in cash, reinforcing Regeneron's commitment to providing tangible returns to its shareholders.
Recently, Regeneron PharmaceuticalsREGN-- has experienced significant developments. A federal court jury has found AmgenAMGN-- liable for antitrust violations, impacting the competitive landscape involving Regeneron’s Praluent® (alirocumab). This legal victory could strengthen Regeneron's market position and potentially enhance its financial outlook. Additionally, RegeneronREGN-- reported a drop in Q1 2025 revenue to $3,029 million. Analysts noted this decline, emphasizing the need for strategic adjustments to bolster future financial performance. Nonetheless, Regeneron remains a formidable player in biotechnology, reflected in its stock performance and strategic initiatives.
Over the past week, Regeneron celebrated young innovators at the 75th Regeneron International Science and Engineering Fair (ISEF), awarding over $9 million in prizes. This event not only underscores Regeneron’s commitment to fostering scientific innovation but also enhances its reputation in the STEM community. By supporting these future leaders, Regeneron is investing in long-term scientific progress, which aligns with its core mission to transform lives through groundbreaking medicines.
In conclusion, Regeneron Pharmaceuticals continues to demonstrate resilience and innovation, both financially and within the scientific community. These recent developments highlight the company's ongoing strategic efforts to maintain its leadership in biotechnology. Investors should note that May 20, 2025, marks the last day to purchase Regeneron stock to qualify for the upcoming dividend. Any acquisitions made after this date will not entitle shareholders to the dividend payout for this period.
Recently, Regeneron PharmaceuticalsREGN-- has experienced significant developments. A federal court jury has found AmgenAMGN-- liable for antitrust violations, impacting the competitive landscape involving Regeneron’s Praluent® (alirocumab). This legal victory could strengthen Regeneron's market position and potentially enhance its financial outlook. Additionally, RegeneronREGN-- reported a drop in Q1 2025 revenue to $3,029 million. Analysts noted this decline, emphasizing the need for strategic adjustments to bolster future financial performance. Nonetheless, Regeneron remains a formidable player in biotechnology, reflected in its stock performance and strategic initiatives.
Over the past week, Regeneron celebrated young innovators at the 75th Regeneron International Science and Engineering Fair (ISEF), awarding over $9 million in prizes. This event not only underscores Regeneron’s commitment to fostering scientific innovation but also enhances its reputation in the STEM community. By supporting these future leaders, Regeneron is investing in long-term scientific progress, which aligns with its core mission to transform lives through groundbreaking medicines.
In conclusion, Regeneron Pharmaceuticals continues to demonstrate resilience and innovation, both financially and within the scientific community. These recent developments highlight the company's ongoing strategic efforts to maintain its leadership in biotechnology. Investors should note that May 20, 2025, marks the last day to purchase Regeneron stock to qualify for the upcoming dividend. Any acquisitions made after this date will not entitle shareholders to the dividend payout for this period.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet